Juvenile pemphigus vulgaris: A narrative review
- PMID: 40419903
- PMCID: PMC12114023
- DOI: 10.1097/MD.0000000000042611
Juvenile pemphigus vulgaris: A narrative review
Abstract
Pemphigus vulgaris is a chronic autoimmune dermatosis that primarily affects the skin and mucous membranes. Juvenile pemphigus vulgaris (JPV), a pediatric variant of pemphigus vulgaris, displays unusual features that may mimic other mucosal lesions. This similarity leads to diagnostic and therapeutic difficulties, often causing delays in diagnosis. Primary treatment consists of systemic corticosteroids and immunosuppressive agents, with biological therapies, such as rituximab, emerging as potential alternatives. Timely diagnosis and treatment are essential to improve prognosis and reduce complications related to long-term immunosuppressive therapy. A comprehensive electronic and manual literature search was conducted using various databases to consolidate the existing literature on JPV, focusing on its epidemiology, pathogenesis, clinical presentation, diagnosis, treatment options, and long-term outcomes in pediatric patients. A detailed review focusing on JPV has been conducted over the last 10 years (2014-2024). A literature review identified 37 cases of JPV in 16 studies. Owing to the rarity of JPV, much of the available evidence relies on case reports and case series, resulting in poorly defined response rates to different treatment options. Additionally, long-term monitoring of patients with disease recurrence is lacking. By identifying gaps in the current knowledge and offering a comprehensive overview, this review seeks to enhance awareness and guide future research and management strategies for JPV.
Keywords: autoimmune; histopathology; juvenile pemphigus vulgaris; pemphigus; vesiculobullous disease.
Copyright © 2025 the Author(s). Published by Wolters Kluwer Health, Inc.
Conflict of interest statement
The authors have no funding and conflicts of interest to disclose.
Figures
Similar articles
-
Pemphigus vulgaris.An Bras Dermatol. 2019 Jul 29;94(3):264-278. doi: 10.1590/abd1806-4841.20199011. An Bras Dermatol. 2019. PMID: 31365654 Free PMC article.
-
Diagnosis, treatment, and long-term outcomes of pediatric pemphigus: a retrospective study at tertiary medical centers.Int J Dermatol. 2024 Dec;63(12):1755-1760. doi: 10.1111/ijd.17251. Epub 2024 May 31. Int J Dermatol. 2024. PMID: 38819034 Free PMC article.
-
Rituximab as the treatment of pemphigus vulgaris in the COVID-19 pandemic era: A narrative review.Dermatol Ther. 2021 Jan;34(1):e14405. doi: 10.1111/dth.14405. Epub 2020 Oct 20. Dermatol Ther. 2021. PMID: 33051960 Free PMC article. Review.
-
Management of pediatric pemphigus vulgaris with rituximab: A case report and review of the literature.Pediatr Dermatol. 2022 Nov;39(6):960-966. doi: 10.1111/pde.15095. Epub 2022 Jul 24. Pediatr Dermatol. 2022. PMID: 35871636 Review.
-
A current review of juvenile pemphigus vulgaris: analysis of data on clinical outcomes.Am J Clin Dermatol. 2010;11(1):21-33. doi: 10.2165/11310380-000000000-00000. Am J Clin Dermatol. 2010. PMID: 20000872 Review.
References
-
- Eming R, Hennerici T, Backlund J, et al. . Pathogenic IgG antibodies against desmoglein 3 in pemphigus vulgaris are regulated by HLA-DRB1*04:02-restricted T cells. J Immunol. 2014;193:4391–9. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical